Elicera Therapeutics Successfully Concludes Preclinical Proof-of-Concept Studies for Oncolytic Virus ELC-201 Confirming Proposed Mode of Action

Gothenburg, April 27, 2022 – Elicera Therapeutics AB (publ) (“Elicera”), a clinical-stage cell and gene therapy company developing next-generation immuno-oncology treatments based on enhanced CAR T cells and oncolytic viruses, today announced that it has concluded preclinical studies proof of concept for its oncolytic virus ELC-201. The study results support the proposed mode of action of ELC-201.

ELC-201 is a next-generation oncolytic virus that has been genetically modified to allow the treatment of most cancers. The drug candidate was armed with Elicera’s proprietary platform technology, iTANK, to elicit a parallel immune response and attack on cancer cells by patients’ own endogenous killer T cells. Additionally, ELC-201 is armed with another immune-stimulating factor, 4-1BBL, to further amplify the anti-cancer immune response.

Preclinical studies, including data from animal models of pancreatic cancer, show that ELC-201:

• Effectively infiltrates and kills tumor cells.
• Effectively induces a parallel (bystander) immune response and stimulates the function of tumor-infiltrating immune cells.
• Better controls tumor growth and increases survival compared to placebo.
• Better controls tumor growth and increases survival compared to the same oncolytic virus but without iTANK and 4-1BBL armament.

“ELC-201 represents the cutting edge of research in the field of cell and gene therapies and the conclusion of preclinical proof-of-concept studies represents an important step in bringing the candidate closer to clinical studies. our lead indication for ELC-201,” says Jamal El MoslehCEO of Elicera Therapeutics. “We are very excited about this asset and see tremendous potential in ELC-201’s ability to treat cancer and elicit a strong parallel immune response against cancer. The concluded preclinical proof-of-concept studies only confirm this. That oncolytic viruses, and not just CAR T cells, armed with iTANK, can also better control tumor growth and increase survival, which also speaks to the potential of the technology platform. »

About ELC-201

ELC-201 is a next-generation oncolytic virus with three combined modes of action in the treatment of cancer. The drug candidate has been genetically engineered with the company’s proprietary immune enhancement platform technology, iTANK, in addition to 4-1BBL, both of which lead to strong activation of the patient’s endogenous killer T cells, leading to a broad parallel attack on cancer cells. . ELC-201 is applicable for the treatment of most cancers.

About the iTANK platform

The iTANK (immunoTherapies Activated with NAP for efficient Killing) platform is the Company’s fully developed technology platform for enhancing and arming CAR T cells. The technology is used to incorporate a transgene into CAR T cells encoding a neutrophil activating protein (NAP) from the bacterium Helicobacter pylori. Upon activation, NAP was shown to be able to enhance CAR T cell function in addition to activating a parallel immune response via endogenous killer T cells. It is expected to be able to generate a broad attack against most cancer cell targets. The iTANK platform is used to boost the company’s own CAR T cells but can also be applied to other CAR T cells under development. Preclinical proof-of-concept data was recently published in Nature Biomedical Engineering and can be found here: https://www.nature.com/articles/s41551-022-00875-5.

For more information, please contact:

Jamal El MoslehCEO, Elicera Therapeutics AB

Telephone: +46 (0) 703 31 90 51
[email protected]

On Elicera Therapeutics AB

Elicera Therapeutics AB is a clinical-stage cell and gene therapy company developing the next generation of immuno-oncology treatments. The work is based on long-standing, high-level research carried out by Professor Magnus Essand’s research group at Uppsala University and resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses. Additionally, Elicera has developed a technology platform called iTANK that can be used to optimize all developing CAR T cells and activate killer T cells against cancer. The Company’s stock (ELIC) is traded on the Nasdaq First North Growth Market. G&W Fondkommission has been appointed as the company’s certified advisor. Email: [email protected], tel. : +468-503 000 50.

For more information, visit www.elicera.com

https://news.cision.com/elicera-therapeutics/r/elicera-therapeutics-successfully-concludes-preclinical-proof-of-concept-studies-for-oncolytic-virus,c3553562

https://mb.cision.com/Main/20218/3553562/1569282.pdf

(c) Decision 2022. All rights reserved., sources Press Releases – English